Xenetic Biosciences (XBIO) Non Operating Income (2014 - 2026)
Xenetic Biosciences' (XBIO) quarterly Non Operating Income came in at $45735.0 in Q1 2026, up 16.47% YoY from $39268.0 in Q1 2025, and up 4.06% on a QoQ basis from $43951.0 in Q4 2025.
Xenetic Biosciences (XBIO) Non Operating Income (2014 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 13 years of Non Operating Income data on file, last reported at $45735.0 in Q1 2026.
- Quarterly Non Operating Income rose 16.47% year-over-year to $45735.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160189.0 (down 23.76% YoY) and the FY2025 annual result came in at $153722.0, down 37.04% from the prior year.
- Non Operating Income improved to $45735.0 in Q1 2026, from $43951.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $147225.0 in Q2 2023 to a low of $14889.0 in Q2 2022.
- A 5-year average of $58253.1 and a median of $45735.0 in 2026 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income soared 888.82% — and 2024, when it plunged 56.92%.
- Tracing XBIO's Non Operating Income over 5 years: stood at $80793.0 in 2022, then grew by 4.17% to $84161.0 in 2023, then plunged by 46.98% to $44624.0 in 2024, then dropped by 1.51% to $43951.0 in 2025, then gained by 4.06% to $45735.0 in 2026.
- The last three Non Operating Income figures came in at $45735.0 (Q1 2026), $43951.0 (Q4 2025), and $34794.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | 41,995.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41,995.00 |
| Mar 31, 2026 | 45,735.00 |
| Dec 31, 2025 | 43,951.00 |
| Sep 30, 2025 | 34,794.00 |
| Jun 30, 2025 | 35,709.00 |
| Mar 31, 2025 | 39,268.00 |
| Dec 31, 2024 | 44,624.00 |
| Sep 30, 2024 | 62,802.00 |
| Jun 30, 2024 | 63,426.00 |
| Mar 31, 2024 | 73,301.00 |
| Dec 31, 2023 | 84,161.00 |
| Sep 30, 2023 | 91,130.00 |
| Jun 30, 2023 | 147,225.00 |
| Mar 31, 2023 | 58,621.00 |
| Dec 31, 2022 | 80,793.00 |
| Sep 30, 2022 | 43,769.00 |
| Jun 30, 2022 | 14,889.00 |
| Mar 31, 2022 | 26,104.00 |
| Dec 31, 2021 | 32,344.00 |
| Sep 30, 2021 | 25,123.00 |